Investigational Drug Information for Brensocatib
✉ Email this page to a colleague
What is the drug development status for Brensocatib?
Brensocatib is an investigational drug.
There have been 8 clinical trials for Brensocatib.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2020.
The most common disease conditions in clinical trials are Fibrosis, Bronchiectasis, and Renal Insufficiency. The leading clinical trial sponsors are Insmed Incorporated, NHS Tayside, and University of Dundee.
There are four US patents protecting this investigational drug and sixty-five international patents.
Summary for Brensocatib
| US Patents | 4 |
| International Patents | 65 |
| US Patent Applications | 23 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2020-12-01) |
| Vendors | 31 |
Recent Clinical Trials for Brensocatib
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants | Insmed Incorporated | Phase 1 |
| A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | Insmed Incorporated | Phase 1 |
| A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants | Insmed Incorporated | Phase 1 |
Clinical Trial Summary for Brensocatib
Top disease conditions for Brensocatib
Top clinical trial sponsors for Brensocatib
US Patents for Brensocatib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Brensocatib | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Try a Trial |
| Brensocatib | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Try a Trial |
| Brensocatib | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | AstraZeneca AB (Sodertalje, SE) | ⤷ Try a Trial |
| Brensocatib | ⤷ Try a Trial | Certain (25)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Brensocatib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Brensocatib | Argentina | AR099177 | 2034-01-24 | ⤷ Try a Trial |
| Brensocatib | Australia | AU2015208932 | 2034-01-24 | ⤷ Try a Trial |
| Brensocatib | Australia | AU2017200338 | 2034-01-24 | ⤷ Try a Trial |
| Brensocatib | Australia | AU2018202956 | 2034-01-24 | ⤷ Try a Trial |
| Brensocatib | Australia | AU2019202675 | 2034-01-24 | ⤷ Try a Trial |
| Brensocatib | Canada | CA2935625 | 2034-01-24 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
